TickerFacts.

Alzamend Neuro, Inc. (ALZN): Shareholders' Equity

Annual figures by period end, from SEC filings.

$733.2K
As of 2026-04-30
$5.80M
As of 2026-07-31
-37.8%
3-year compound annual growth
-18.3%
5-year compound annual growth
$13.35M2020-04-30: $821.7K2021-04-30: $2.01M2022-04-30: $13.35M2023-04-30: $3.05M2024-04-30: -$2.59M2025-04-30: $3.97M2026-04-30: $733.2K$733.2K
2020-04-30 Shareholders' Equity (USD) 2026-04-30
Period endedShareholders' EquityChange YoYSource filing
2026-04-30$733.2K-81.5%2026-07-22, Balance as of period end
2025-04-30$3.97Mn/m2026-07-22, Balance as of period end
2024-04-30-$2.59Mn/m2025-07-22, Balance as of period end
2023-04-30$3.05M-77.2%2024-07-30, Balance as of period end
2022-04-30$13.35M+563.3%2023-07-27, Balance as of period end
2021-04-30$2.01M+145.0%2022-07-19, Balance as of period end
2020-04-30$821.7Kn/a2021-07-29, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Alzamend Neuro, Inc. (ALZN)2026-04-30$733.2K-81.5%
Inhibitor Therapeutics, Inc. (INTI)2025-12-31-$1.29Mn/m
Accustem Sciences Inc. (ACUT)2025-12-31-$3.40Mn/m
Artelo Biosciences, Inc. (ARTL)2025-12-31-$1.27Mn/m
BullFrog AI Holdings, Inc. (BFRG)2025-12-31$2.14M-57.0%
Neonc Technologies Holdings, Inc. (NTHI)2025-12-31-$17.51Mn/m
Avenue Therapeutics, Inc. (ATXI)2025-12-31$1.83M-34.5%
Alaunos Therapeutics, Inc. (TCRT)2025-12-31$2.15M+4.4%
InMed Pharmaceuticals Inc. (INM)2026-06-30$1.08M-92.0%

Compare ALZN, INTI, ACUT, ARTL side by side · Screen every company in Pharmaceutical Preparations ↗